These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 25354875

  • 1. FOXP3+ regulatory T-cell counts correlate with histological response in Crohn's colitis treated with infliximab.
    Sloan S, Maxwell P, Salto-Tellez M, Loughrey MB.
    Pathol Int; 2014 Dec; 64(12):624-7. PubMed ID: 25354875
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease.
    Van den Brande JM, Koehler TC, Zelinkova Z, Bennink RJ, te Velde AA, ten Cate FJ, van Deventer SJ, Peppelenbosch MP, Hommes DW.
    Gut; 2007 Apr; 56(4):509-17. PubMed ID: 17082252
    [Abstract] [Full Text] [Related]

  • 5. Pre-clinical Crohn's disease: diagnosis, treatment and six year follow-up.
    Sorrentino D, Avellini C, Geraci M, Vadalà S.
    J Crohns Colitis; 2014 Jul; 8(7):702-7. PubMed ID: 24411923
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Identification of inflammatory mediators in patients with Crohn's disease unresponsive to anti-TNFα therapy.
    Leal RF, Planell N, Kajekar R, Lozano JJ, Ordás I, Dotti I, Esteller M, Masamunt MC, Parmar H, Ricart E, Panés J, Salas A.
    Gut; 2015 Feb; 64(2):233-42. PubMed ID: 24700437
    [Abstract] [Full Text] [Related]

  • 8. Heightened Expression of CD39 by Regulatory T Lymphocytes Is Associated with Therapeutic Remission in Inflammatory Bowel Disease.
    Gibson DJ, Elliott L, McDermott E, Tosetto M, Keegan D, Byrne K, Martin ST, Rispens T, Cullen G, Mulcahy HE, Cheifetz AS, Moss AC, Robson SC, Doherty GA, Ryan EJ.
    Inflamm Bowel Dis; 2015 Dec; 21(12):2806-14. PubMed ID: 26332314
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease.
    Geboes K, Rutgeerts P, Opdenakker G, Olson A, Patel K, Wagner CL, Marano CW.
    Curr Med Res Opin; 2005 Nov; 21(11):1741-54. PubMed ID: 16307694
    [Abstract] [Full Text] [Related]

  • 13. T2 enhances in situ level of Foxp3+ regulatory cells and modulates inflammatory cytokines in Crohn's disease.
    Li G, Ren J, Wang G, Gu G, Hu D, Ren H, Hong Z, Wu X, Liu S, Li J.
    Int Immunopharmacol; 2014 Feb; 18(2):244-8. PubMed ID: 24369313
    [Abstract] [Full Text] [Related]

  • 14. Discrete changes in circulating regulatory T cells during infliximab treatment of Crohn's disease.
    Hvas CL, Kelsen J, Agnholt J, Dige A, Christensen LA, Dahlerup JF.
    Autoimmunity; 2010 Jun; 43(4):325-33. PubMed ID: 20298123
    [Abstract] [Full Text] [Related]

  • 15. Infliximab inhibits activation and effector functions of peripheral blood T cells in vitro from patients with clinically active ulcerative colitis.
    Dahlén R, Strid H, Lundgren A, Isaksson S, Raghavan S, Magnusson MK, Simrén M, Sjövall H, Öhman L.
    Scand J Immunol; 2013 Sep; 78(3):275-84. PubMed ID: 23713660
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Use of a 99mTc labeled anti-TNFalpha monoclonal antibody in Crohn's disease: in vitro and in vivo studies.
    D'Alessandria C, Malviya G, Viscido A, Aratari A, Maccioni F, Amato A, Scopinaro F, Caprilli R, Signore A.
    Q J Nucl Med Mol Imaging; 2007 Dec; 51(4):334-42. PubMed ID: 17464276
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Response, relapse and mucosal immune regulation after infliximab treatment in fistulating Crohn's disease.
    Agnholt J, Dahlerup JF, Buntzen S, Tøttrup A, Nielsen SL, Lundorf E.
    Aliment Pharmacol Ther; 2003 Mar 01; 17(5):703-10. PubMed ID: 12641520
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.